Amphastar Pharmaceuticals (AMPH) Aktienübersicht
Amphastar Pharmaceuticals, Inc. ist ein biopharmazeutisches Unternehmen, das generische und proprietäre injizierbare, inhalative und intranasale Produkte in den Vereinigten Staaten, China und Frankreich entwickelt, herstellt, vermarktet und verkauft. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 6/6 |
| Künftiges Wachstum | 1/6 |
| Vergangene Leistung | 2/6 |
| Finanzielle Gesundheit | 3/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
AMPH Community Fair Values
Create NarrativeSee what 44 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Amphastar Pharmaceuticals, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$18.45 |
| 52-Wochen-Hoch | US$31.26 |
| 52-Wochen-Tief | US$17.03 |
| Beta | 0.97 |
| 1 Monat Veränderung | -9.43% |
| 3 Monate Veränderung | -35.42% |
| 1 Jahr Veränderung | -24.20% |
| 3 Jahre Veränderung | -55.82% |
| 5 Jahre Veränderung | -7.57% |
| Veränderung seit IPO | 84.32% |
Aktuelle Nachrichten und Updates
Analyse-Update • May 10
AMPH: Buybacks And New Approvals Will Support Future Upside Potential
Narrative Update on Amphastar Pharmaceuticals The latest analyst work has trimmed Amphastar Pharmaceuticals' implied fair value to about $26.86 from $28.00, as analysts factor in recent price target cuts from multiple firms and a slightly higher discount rate tied to softer revenue guidance despite recent product approvals. Analyst Commentary Recent research on Amphastar Pharmaceuticals has turned more cautious, with multiple firms trimming price targets and one downgrade reflecting concerns around revenue guidance and execution, even as new products win approvals.Seeking Alpha • Apr 30
Amphastar: A Cheap Multiple Doing Exactly What It's Supposed To Do
Summary Amphastar Pharmaceuticals trades at a deep discount—6.7x trailing earnings—reflecting structural growth and margin challenges. Branded product growth (BAQSIMI, Primatene MIST) has not offset accelerating legacy generic erosion, resulting in flat or declining revenues. 2026 guidance has already been cut; gross margins are guided lower, and consensus estimates likely remain too high heading into Q1 earnings. I maintain a HOLD rating, leaning bearish, pending a clean AMP-007 launch or transformative business development. Read the full article on Seeking Alpha
Analyse-Update • Apr 24
AMPH: Revised Outlook Suggests Future Upside As New Therapies Scale
Narrative Update on Amphastar Pharmaceuticals The analyst price target for Amphastar Pharmaceuticals has shifted from $38 to $30 as analysts factor in revised revenue guidance, lower projected profit margins, and a higher assumed future P/E multiple. They also note the potential importance of AMP-007 for achieving mid to high single digit revenue growth targets.Recent updates
Analyse-Update • May 10
AMPH: Buybacks And New Approvals Will Support Future Upside Potential
Narrative Update on Amphastar Pharmaceuticals The latest analyst work has trimmed Amphastar Pharmaceuticals' implied fair value to about $26.86 from $28.00, as analysts factor in recent price target cuts from multiple firms and a slightly higher discount rate tied to softer revenue guidance despite recent product approvals. Analyst Commentary Recent research on Amphastar Pharmaceuticals has turned more cautious, with multiple firms trimming price targets and one downgrade reflecting concerns around revenue guidance and execution, even as new products win approvals.Seeking Alpha • Apr 30
Amphastar: A Cheap Multiple Doing Exactly What It's Supposed To Do
Summary Amphastar Pharmaceuticals trades at a deep discount—6.7x trailing earnings—reflecting structural growth and margin challenges. Branded product growth (BAQSIMI, Primatene MIST) has not offset accelerating legacy generic erosion, resulting in flat or declining revenues. 2026 guidance has already been cut; gross margins are guided lower, and consensus estimates likely remain too high heading into Q1 earnings. I maintain a HOLD rating, leaning bearish, pending a clean AMP-007 launch or transformative business development. Read the full article on Seeking AlphaAnalyse-Update • Apr 24
AMPH: Revised Outlook Suggests Future Upside As New Therapies Scale
Narrative Update on Amphastar Pharmaceuticals The analyst price target for Amphastar Pharmaceuticals has shifted from $38 to $30 as analysts factor in revised revenue guidance, lower projected profit margins, and a higher assumed future P/E multiple. They also note the potential importance of AMP-007 for achieving mid to high single digit revenue growth targets.Analyse-Update • Apr 10
AMPH: Share Repurchases And New Launches Will Support Future Upside Potential
Analysts have trimmed Amphastar Pharmaceuticals' fair value estimate by $1 to about $28, reflecting lower Street price targets and cautious views on revised revenue guidance despite recent product approvals. Analyst Commentary Recent Street research on Amphastar shares points to a more cautious tone after the latest revenue guidance update and lower price targets, even as new products move through the approval pipeline.Analyse-Update • Mar 26
AMPH: Softer Guidance And Execution Risk Will Shape Future Upside Potential
Analysts have trimmed Amphastar Pharmaceuticals' fair value estimate from $32.00 to $29.00. This reflects updated views on softer revenue guidance, lower projected profit margins, a slightly higher discount rate, and a higher assumed future P/E multiple in light of recent price target cuts to $30.00 from several firms.
Analyse-Update • Mar 12
AMPH: Softer Guidance And Pipeline Risk Will Still Support Future Upside
Analysts have modestly reduced their price targets on Amphastar Pharmaceuticals to $30, reflecting concerns about softer revenue guidance and pipeline execution risk. At the same time, recent product approvals and revised earnings assumptions support a slightly higher modeled fair value and P/E multiple in our framework.Analyse-Update • Feb 26
AMPH: Pipeline Execution Risk Will Cap Upside Despite Lowered US$30 Outlook
Analysts have trimmed their price target on Amphastar Pharmaceuticals to $30 from $31, citing cautious views on pipeline execution risk, even as they still see the shares as undervalued relative to peers and historical valuation. Analyst Commentary Recent research updates reflect a more cautious tone, with bearish analysts trimming price expectations even while acknowledging that Amphastar still trades at what they view as a discount to peers and its own history.Analyse-Update • Feb 09
AMPH: Pipeline Execution Risk Will Drive Cautious View Despite Lowered US$30 Outlook
Analysts have trimmed their price target on Amphastar Pharmaceuticals to US$30 from US$31, reflecting a cautious view on pipeline execution risk, even as they see the shares as undervalued relative to historical and peer valuations. Analyst Commentary Bearish analysts have trimmed their price target on Amphastar Pharmaceuticals to US$30 from US$31 as coverage transitions, signaling a cautious stance on how the company can deliver on its current pipeline while justifying its valuation.Analyse-Update • Jan 25
AMPH: Buybacks And Pipeline Risk Will Shape Cautious Yet Balanced Outlook
Analysts have trimmed their price target on Amphastar Pharmaceuticals to $30 from $31, reflecting updated views on revenue growth, margin assumptions, and future P/E expectations, along with ongoing caution around pipeline execution risk. Analyst Commentary Bearish analysts have taken a slightly more cautious stance, trimming the price target to US$30 from US$31 as coverage transitions to a new lead.Analyse-Update • Jan 11
AMPH: Pipeline Execution Risk Will Shape Cautious View Despite Buybacks
Analysts have trimmed their price target on Amphastar Pharmaceuticals to $30 from $31. The revised target reflects fresh coverage that balances a view of the shares as undervalued on comps and historical valuation with caution around pipeline execution risk.Analyse-Update • Dec 13
AMPH: Q3 Drug Trends And Buybacks Will Shape Balanced Near-Term Outlook
Analysts have modestly lowered their price target on Amphastar Pharmaceuticals to $31 from $32, citing recent Q3 pricing and volume trends for key drugs and a largely unchanged outlook for near term earnings and 2026 estimates. Analyst Commentary Bearish analysts have highlighted that the modest reduction in the price target reflects growing caution around the durability of Amphastar's recent performance, particularly in light of more muted pricing and volume trends observed in the third quarter.Analyseartikel • Jul 01
Earnings Working Against Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Share Price
Amphastar Pharmaceuticals, Inc.'s ( NASDAQ:AMPH ) price-to-earnings (or "P/E") ratio of 7.6x might make it look like a...Analyseartikel • Apr 04
We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Stay On Top Of Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Feb 19
Amphastar Pharmaceuticals: A Gradual Strategy
Summary Amphastar Pharmaceuticals has a growth model based on organic growth and acquisitions, though competition and patent expirations pose risks. Financially, Amphastar has a strong revenue trend but faces potential growth slowdowns, especially in 2025. A fair value estimate derived from a DCF model and backed by a comparison with peers is $43.24, which suggests a 40% upside. My strategy includes a 0.75x position weight and a gradual approach combining the stock with a Covered Call. Read the full article on Seeking AlphaAnalyseartikel • Jan 03
These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Reasonably Well
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Dec 16
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Prospects Need A Boost To Lift Shares
With a price-to-earnings (or "P/E") ratio of 12.9x Amphastar Pharmaceuticals, Inc. ( NASDAQ:AMPH ) may be sending...Analyseartikel • Nov 28
Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Seeking Alpha • Oct 25
Amphastar: Objectively Undervalued But For Good Reason (Rating Downgrade)
Summary Amphastar's Q2 2024 revenue grew 25% year-over-year to $182.4 million, primarily driven by BAQSIMI and Primatene MIST sales. Primatene MIST faces future challenges as its key patent expires in 2026, limiting long-term revenue potential. BAQSIMI contributed $38.5 million in Q2 2024 sales, affirming its strategic acquisition from Eli Lilly. Amphastar’s heavy reliance on a few high-margin products, like glucagon and epinephrine, may limit future growth due to rising competition. I recommend holding Amphastar as current valuations seem fair, but growth prospects are uncertain due to product competition and patent expirations. Read the full article on Seeking AlphaAnalyseartikel • Sep 15
Investors Continue Waiting On Sidelines For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)
Amphastar Pharmaceuticals, Inc.'s ( NASDAQ:AMPH ) price-to-earnings (or "P/E") ratio of 14.1x might make it look like a...Seeking Alpha • Sep 12
Amphastar: Perplexing Pipeline, Lumpy Revenues - I'm On Sidelines
Summary Amphastar Pharmaceuticals has seen significant growth since its 2014 IPO, with its stock price increasing over 500% to $45 per share. The acquisition of Baqsimi from Eli Lilly is a key revenue driver, but its long-term profitability remains uncertain due to milestone payments. Amphastar's revenue growth from epinephrine and Primatene Mist may not be sustainable, and the company faces intense competition in these markets. The pipeline's future is unclear, with several FDA rejections and no standout products, leading to a "Hold" rating on Amphastar stock. Read the full article on Seeking Alpha
Neue Analyse • Sep 10
Decisive Acquisitions And Production Innovations Propel Pharma Growth And Market Dominance
Emphasis on proprietary products and strategic acquisitions to enhance market presence and contribute significantly to revenue growth.Analyseartikel • Aug 27
Is Amphastar Pharmaceuticals (NASDAQ:AMPH) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analyseartikel • Jul 05
Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Seeking Alpha • Jul 01
Amphastar Pharmaceuticals: Shining Star Soon To Fade With Competitive Pressures Looming
Summary AMPH has materially benefited from a variety of temporary factors across their key product lines that have largely gone unnoticed by investors, sending shares up ~100% over the last 3yrs. Amphastar’s glucagon business has benefited from shortages at Fresenius, which were recently rectified. Three new competitors are about to launch glucagon, turning this duopoly into a potential 5-player market. Epinephrine revenues should meaningfully disappoint as shortage benefits alleviate, a newly approved competitor ramps, and two potential competitors gain approval. The sole Orange Book patent on Primatene MIST, a key high margin product, expires in January 2026, which opens the door to material competition. Primatene is one of the few DTC products in its aisle without a generic. A handful of smaller “Other” products have been buoyed by a tornado which took out competitor Pfizer’s product warehousing. The magnitude of the benefit is larger than investors believe, and Pfizer is quickly returning to market. Read the full article on Seeking AlphaAnalyseartikel • May 30
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 17x, you may...Seeking Alpha • May 30
Amphastar Pharmaceuticals: Buy When Fear Is Overblown
Summary Seeking Alpha's screener identified Amphastar Pharmaceuticals as a potential investment candidate based on its solid financials, positive growth in revenue and earnings. Despite its strong financials and potential for earnings growth, the company's stock fell 31% in 5 months. The article aims to uncover the reasons behind the price decline to determine if the price decline is a temporary setback that offers an opportunity for value investors. Read the full article on Seeking AlphaSeeking Alpha • May 15
Reassessing Amphastar Pharmaceuticals
Summary Amphastar Pharmaceuticals, Inc. stock is down approximately 30% this year, and the company reported mixed Q1 results last week. Despite the poor performance of the stock so far in 2024, there are some positives on the company and its stock. An updated analysis around Amphastar Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking AlphaAnalyseartikel • Mar 27
Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Mar 04
Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions
Summary Amphastar Pharmaceuticals specializes in developing, manufacturing, and distributing pharmaceutical products, with a focus on strategic acquisitions. The company's portfolio includes high-margin products such as Primatene MIST and Glucagon Injection for severe hypoglycemia. Amphastar's pipeline includes promising upcoming products such as Rextovy, and its recent acquisition of Baqsimi enhances its position in diabetes management. AMPH's financials indicate manageable debt levels and the potential for continued revenue growth and profitability, reinforcing its investment appeal. My valuation analysis suggests AMPH is undervalued compared to peers, with strong business fundamentals supporting a "Strong Buy" rating. Read the full article on Seeking AlphaAnalyseartikel • Jan 04
Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analyseartikel • Dec 20
Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E
With a price-to-earnings (or "P/E") ratio of 21.4x Amphastar Pharmaceuticals, Inc. ( NASDAQ:AMPH ) may be sending...Analyseartikel • Dec 03
Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Aktionärsrenditen
| AMPH | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | -18.9% | -1.5% | 2.6% |
| 1Y | -24.2% | 30.4% | 26.2% |
Rendite im Vergleich zur Industrie: AMPH unter dem Niveau der Branche US Pharmaceuticals , die im vergangenen Jahr eine Rendite von 30.4% erzielte.
Rendite vs. Markt: AMPH hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 26.2 erzielte.
Preisvolatilität
| AMPH volatility | |
|---|---|
| AMPH Average Weekly Movement | 10.8% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiler Aktienkurs: AMPH hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: AMPHDie wöchentliche Volatilität (11%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1996 | 1,976 | Jack Zhang | www.amphastar.com |
Amphastar Pharmaceuticals, Inc. ist ein biopharmazeutisches Unternehmen, das generische und proprietäre injizierbare, inhalative und intranasale Produkte in den Vereinigten Staaten, China und Frankreich entwickelt, herstellt, vermarktet und verkauft. Es bietet BAQSIMI, ein trockenes Nasenspray, das im Notfall zur Behandlung von schwerer Hypoglykämie eingesetzt wird; Primatene MIST, ein Epinephrin-Inhalationsprodukt zur vorübergehenden Linderung leichter Symptome von intermittierendem Asthma; Glucagon zur Injektion Notfall-Kit; Enoxaparin, eine injizierbare Form von niedermolekularem Heparin zur Vorbeugung und Behandlung von tiefen Venenthrombosen; und REXTOVY und Naloxon für Opioid-Überdosierung. Das Unternehmen bietet auch Cortrosyn, eine gefriergetrocknete Kraft zur Verwendung als diagnostisches Mittel beim Screening von Patienten mit Nebennierenrindeninsuffizienz; Amphadase, eine Hyaluronidase-Injektion auf Rinderbasis; Epinephrin-Injektion für allergische Reaktionen; Lidocain-Gelee, ein Anästhetikum für urologische Eingriffe; Lidocain-Lösung für verschiedene Eingriffe; Phytonadion-Injektion, eine Vitamin-K1-Injektion für Neugeborene; und Notfallspritzen, einschließlich Atropin, Kalziumchlorid, Dextrose, Epinephrin, Lidocain und Natriumbicarbonat.
Amphastar Pharmaceuticals, Inc.'s Grundlagenzusammenfassung
| AMPH grundlegende Statistiken | |
|---|---|
| Marktanteil | US$837.77m |
| Gewinn(TTM) | US$79.23m |
| Umsatz(TTM) | US$720.53m |
10.3x
Kurs-Gewinn-Verhältnis 1.1x
Kurs-Umsatz-VerhältnisIst AMPH zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| AMPH Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$720.53m |
| Kosten der Einnahmen | US$379.40m |
| Bruttogewinn | US$341.13m |
| Sonstige Ausgaben | US$261.90m |
| Gewinn | US$79.23m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 1.80 |
| Bruttomarge | 47.34% |
| Nettogewinnspanne | 11.00% |
| Schulden/Eigenkapital-Verhältnis | 79.0% |
Wie hat sich AMPH auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/11 06:27 |
| Aktienkurs zum Tagesende | 2026/05/11 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Amphastar Pharmaceuticals, Inc. wird von 14 Analysten beobachtet. 6 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Glen Santangelo | Barclays |
| Gary Nachman | BMO Capital Markets Equity Research |
| Jason Matthew Gerberry | BofA Global Research |